Role of dynamic and parametric whole-body FDG PET/CT imaging in molecular characterization of primary breast cancer: a single institution experience

A deep learning method for total-body dynamic PET imaging with dual-time-window protocols

PURPOSE

Prolonged scanning durations are one of the primary barriers to the widespread clinical adoption of dynamic Positron Emission Tomography (PET). In this paper, we developed a deep learning algorithm that capable of predicting dynamic images from dual-time-window protocols, thereby shortening the scanning time.

METHODS

This study includes 70 patients (mean age ± standard deviation, 53.61 ± 13.53 years; 32 males) diagnosed with pulmonary nodules or breast nodules between 2022 to 2024. Each patient underwent a 65-min dynamic total-body [18F]FDG PET/CT scan. Acquisitions using early-stop protocols and dual-time-window protocols were simulated to reduce the scanning time. To predict the missing frames, we developed a bidirectional sequence-to-sequence model with attention mechanism (Bi-AT-Seq2Seq); and then compared the model with unidirectional or non-attentional models in terms of Mean Absolute Error (MAE), Bias, Peak Signal-to-Noise Ratio (PSNR), and Structural Similarity (SSIM) of predicted frames. Furthermore, we reported the comparison of concordance correlation coefficient (CCC) of the kinetic parameters between the proposed method and traditional methods.

RESULTS

The Bi-AT-Seq2Seq significantly outperform unidirectional or non-attentional models in terms of MAE, Bias, PSNR, and SSIM. Using a dual-time-window protocol, which includes a 10-min early scan followed by a 5-min late scan, improves the four metrics of predicted dynamic images by 37.31%, 36.24%, 7.10%, and 0.014% respectively, compared to the early-stop protocol with a 15-min acquisition. The CCCs of tumor' kinetic parameters estimated with recovered full time-activity-curves (TACs) is higher than those with abbreviated TACs.

CONCLUSION

The proposed algorithm can accurately generate a complete dynamic acquisition (65 min) from dual-time-window protocols (10 + 5 min).

Increased lesion detectability in patients with locally advanced breast cancer-A pilot study using dynamic whole-body [18F]FDG PET/CT

BACKGROUND

Accurate diagnosis of axillary lymph node (ALN) metastases is essential for prognosis and treatment planning in breast cancer. Evaluation of ALN is done by ultrasound, which is limited by inter-operator variability, and by sentinel lymph node biopsy and/or ALN dissection, none of which are without risks and/or long-term complications. It is known that conventional 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) has limited sensitivity for ALN metastases. However, a recently developed dynamic whole-body (D-WB) [18F]FDG PET/CT scanning protocol, allowing for imaging of tissue [18F]FDG metabolic rate (MRFDG), has been shown to have the potential to increase lesion detectability. The study purpose was to examine detectability of malignant lesions in D-WB [18F]FDG PET/CT compared to conventional [18F]FDG PET/CT.

RESULTS

This study prospectively included ten women with locally advanced breast cancer who were referred for an [18F]FDG PET/CT as part of their diagnostic work-up. They all underwent D-WB [18F]FDG PET/CT, consisting of a 6 min single bed dynamic scan over the chest region started at the time of tracer injection, a 64 min dynamic WB PET scan consisting of 16 continuous bed motion passes, and finally a contrast-enhanced CT scan, with generation of MRFDG parametric images. Lesion visibility was assessed by tumor-to-background and contrast-to-noise ratios using volumes of interest isocontouring tumors with a set limit of 50% of SUVmax and background volumes placed in the vicinity of tumors. Lesion visibility was best in the MRFDG images, with target-to-background values 2.28 (95% CI: 2.04-2.54) times higher than target-to-background values in SUV images, and contrast-to-noise values 1.23 (95% CI: 1.12-1.35) times higher than contrast-to-noise values in SUV images. Furthermore, five imaging experts visually assessed the images and three additional suspicious lesions were found in the MRFDG images compared to SUV images; one suspicious ALN, one suspicious parasternal lymph node, and one suspicious lesion located in the pelvic bone.

CONCLUSIONS

D-WB [18F]FDG PET/CT with MRFDG images show potential for improved lesion detectability compared to conventional SUV images in locally advanced breast cancer. Further validation in larger cohorts is needed.

CLINICAL TRIAL REGISTRATION

The trial is registered in clinicaltrials.gov, NCT05110443, https://www.

CLINICALTRIALS

gov/study/NCT05110443?term=NCT05110443&rank=1 .

Four-dimensional quantitative analysis using FDG-PET in clinical oncology

Positron emission tomography (PET) with F-18 fluorodeoxyglucose (FDG) has been commonly used in many oncological areas. High-resolution PET permits a three-dimensional analysis of FDG distributions on various lesions in vivo, which can be applied for tissue characterization, risk analysis, and treatment monitoring after chemoradiotherapy and immunotherapy. Metabolic changes can be assessed using the tumor absolute FDG uptake as standardized uptake value (SUV) and metabolic tumor volume (MTV). In addition, tumor heterogeneity assessment can potentially estimate tumor aggressiveness and resistance to chemoradiotherapy. Attempts have been made to quantify intratumoral heterogeneity using radiomics. Recent reports have indicated the clinical feasibility of a dynamic FDG PET-computed tomography (CT) in pilot cohort studies of oncological cases. Dynamic imaging permits the assessment of temporal changes in FDG uptake after administration, which is particularly useful for differentiating pathological from physiological uptakes with high diagnostic accuracy. In addition, several new parameters have been introduced for the in vivo quantitative analysis of FDG metabolic processes. Thus, a four-dimensional FDG PET-CT is available for precise tissue characterization of various lesions. This review introduces various new techniques for the quantitative analysis of FDG distribution and glucose metabolism using a four-dimensional FDG analysis with PET-CT. This elegant study reveals the important role of tissue characterization and treatment strategies in oncology.